Why Stem Cell-Derived Islets Struggle After Transplant—and What Researchers Found

One of the biggest hurdles in using stem cell-derived islets to treat Type 1 diabetes is survival after transplantation. When islets are first placed into the body, they enter a harsh environment with limited blood supply and low oxygen levels. This hypoxic stress—a period of inadequate oxygen—damages the cells and reduces their ability to produce insulin.

Previous research has studied how lab-grown islets handle long-term low oxygen. But scientists hadn't directly compared how lab-grown islets and natural human islets respond during the critical acute (short-term) phase right after transplant. A new study published in Scientific Reports fills this gap.

Researchers exposed both stem cell-derived islets and primary human islets to acute hypoxia—1% oxygen—for 48 hours, then analyzed gene activity and cell behavior at the single-cell level.

The results were striking: the two islet types responded in opposite ways. Primary human islets entered what researchers call an 'energy-conserving response.' They quieted down genes essential for beta cell identity (PDX1 and MAFA), suppressed death signals, and shifted into a state of metabolic rest. Think of it as natural islets going into protective hibernation.

Stem cell-derived islets did the opposite. They became metabolically active, shifted heavily toward glycolysis (sugar metabolism), showed signs of lineage instability—meaning the cells lost their specialized identity—and activated pro-apoptotic pathways, which trigger cell death. Lab-grown islets essentially panicked under low oxygen.

Both types of islets lost their ability to respond to glucose and release appropriate amounts of insulin when exposed to hypoxia. But the mechanism differed. In primary islets, insulin secretion was suppressed—the cells simply held back. In stem cell-derived islets, insulin release became dysregulated and unresponsive to glucose changes.

This distinction matters. It suggests that to rescue lab-grown islet function, scientists may need different strategies than those that would help natural islets.

This study reveals why stem cell-derived islets are particularly vulnerable in the post-transplant environment: they lack the stable, protective mechanisms that natural islets have evolved. Their plastic, unstable phenotype—while valuable during development and growth—becomes a liability under stress.

The researchers created a detailed genetic and functional map of these differences. That map is now available to the research community as a resource for designing targeted interventions. Future therapies might boost the protective pathways in lab-grown islets, stabilize their identity under hypoxia, or reduce their metabolic demand during the critical early transplant phase.

This work doesn't solve the transplant problem yet, but it illuminates exactly where the vulnerability lies—a crucial first step toward making stem cell-derived islet therapy more effective for people with Type 1 diabetes.

Source: Scientific reports. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.